
    
      OBJECTIVES:

        -  Assess the therapeutic activity of docetaxel and cisplatin in patients with untreated
           stage IIIA non-small cell lung cancer.

        -  Determine the safety of this regimen in these patients.

      OUTLINE: This is a multicenter study.

      Patients receive docetaxel IV over 1 hour on day 1 and cisplatin IV over 30 minutes on days 1
      and 2. Treatment continues every 3 weeks for 3 courses in the absence of disease progression
      or unacceptable toxicity.

      Patients are followed for survival.

      PROJECTED ACCRUAL: A total of 24-40 patients will be accrued for this study.
    
  